Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271980 · ClinicalTrials.gov registry record
Early-Onset Colorectal Cancer Recurrence
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 177
- Enrollment target
NCT06271980: Completed study, sponsored by City of Hope Medical Center.
NCT06271980 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 177 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06271980 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 177 participants
- Enrollment target
Study Summary
Survivors of early-onset colorectal cancer (diagnosed before age 50) may experience colorectal cancer recurrence several years after curative-intent treatments, but clinical guidelines provide unclear guidance on endoscopic surveillance. This study aims to predict recurrence-free survival and overall survival, in survivors of early-onset colorectal cancer, using a tumor-based molecular assay based on microRNA (ribonucleic acid)
Primary Outcome
Time from disease treatment to development of recurrent colorectal cancer
Interventions
- OTHER ENCORE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2023-04-15 |
| Est. Completion | 2024-02-01 |
What the finished NCT06271980 record still lists
NCT06271980 is an observational study that tracks outcomes without assigning an intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ENCORE is the first listed.
NCT06271980 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06271980 about?
NCT06271980 is a clinical study titled "Early-Onset Colorectal Cancer Recurrence". Survivors of early-onset colorectal cancer (diagnosed before age 50) may experience colorectal cancer recurrence several years after curative-intent treatments, but clinical guidelines provide unclear guidance on endoscopic surveillance. This study aims to predict recurrence-free survival and overa...
What is the current status of trial NCT06271980?
This trial is currently completed. The enrollment target is 177 participants. The study started on 2023-04-15. Estimated completion is 2024-02-01.
What interventions are being tested in trial NCT06271980?
The interventions under investigation include: ENCORE (OTHER).
Who is sponsoring clinical trial NCT06271980?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI